Swiss Rockets AG, a Basel-based biotechnology group, has announced a definitive agreement to acquire U.S. life sciences company Complete Genomics. This strategic acquisition is set to enhance Swiss Rockets' capabilities in targeted cancer therapies and next-generation vaccines by integrating advanced genomic sequencing technologies. The move signals a major step in the company's mission to expand access to precision medicine globally.
A Strategic Move in Precision Medicine
The transaction involves a share purchase agreement for 100% of Complete Genomics, alongside expanded licensing and supply agreements. By incorporating Complete Genomics' expertise, Swiss Rockets aims to strengthen its oncology-focused portfolio, which spans from pre-clinical to late clinical stages. This integration provides a powerful platform for developing more effective and personalized treatments for patients.
The synergy between the two companies is central to the deal, combining Swiss Rockets' focus on novel therapies with Complete Genomics' history in next-generation sequencing (NGS). This partnership is designed to accelerate the development of innovative diagnostics and treatments by leveraging cost-effective sequencing solutions. The ultimate goal is to create a more robust pipeline for precision medicine applications.
Operational Continuity and Future Leadership
Following the acquisition, Complete Genomics will continue to operate as a U.S.-based company, ensuring stability for its customer base. Its management team will retain responsibility for day-to-day operations, product strategy, software development, and customer relationships. This approach guarantees customers can expect continuity across all products, services, and support channels.
Leadership for the newly acquired entity will be spearheaded by Dr. Vladimir Cmiljanovic, the Founder and CEO of Swiss Rockets AG, who will also assume the role of CEO. This appointment ensures the parent company's strategic vision is closely aligned with the operational direction of Complete Genomics. The full management team is expected to be announced at a later date.
Transaction Details and Regulatory Path
The definitive agreement is subject to customary closing conditions, including pending approvals from the shareholders of MGI, Complete Genomics' current parent company. Furthermore, the transaction requires clearance from U.S. regulatory authorities before it can be finalized. These steps are standard procedure for an international acquisition of this scale in the life sciences sector.
The deal has already achieved a significant milestone by receiving approval from Chinese authorities, where Complete Genomics' parent company is based. This initial green light paves the way for the remaining approvals, which are anticipated in the coming months. Successful completion will formalize the transfer of ownership and mark the official start of the new collaboration.
Perspectives from Leadership
Dr. Vladimir Cmiljanovic expressed enthusiasm for the acquisition, highlighting Complete Genomics' strong position in developing cost-effective sequencing solutions. He stated that Swiss Rockets saw an opportunity to accelerate innovation, expand market reach, and enhance supply chain resilience. Cmiljanovic affirmed his commitment to supporting the team in advancing their technology and global research impact.
Dr. Rade Drmanac, Founder of Complete Genomics, described the transaction as the beginning of the company's next growth phase. He noted that Swiss Rockets shares a long-term vision for sequencing innovation and supports the strategy to broaden product adoption. Drmanac also emphasized the importance of strengthening operational independence and diversifying the company's manufacturing footprint.
This acquisition represents a significant convergence of Swiss therapeutic innovation and American genomic sequencing prowess. By joining forces, Swiss Rockets and Complete Genomics are poised to accelerate advancements in oncology and personalized healthcare, promising more precise diagnostics and targeted treatments. The deal strengthens both companies' market positions and reinforces the global effort to combat complex diseases through collaborative science.